TY - JOUR
T1 - Influence of obesity on breast density reduction by omega-3 fatty acids
T2 - Evidence from a randomized clinical trial
AU - Sandhu, Narinder
AU - Schetter, Susann E.
AU - Liao, Jason
AU - Hartman, Terryl J.
AU - Richie, John P.
AU - McGinley, John
AU - Thompson, Henry J.
AU - Prokopczyk, Bogdan
AU - DuBrock, Cynthia
AU - Signori, Carina
AU - Hamilton, Christopher
AU - Calcagnotto, Ana
AU - Trushin, Neil
AU - Aliaga, Cesar
AU - Demers, Laurence M.
AU - El-Bayoumy, Karam
AU - Manni, Andrea
N1 - Publisher Copyright:
© 2015 AACR.
PY - 2016/4
Y1 - 2016/4
N2 - Preclinical data indicate that omega-3 fatty acids (n-3FA) potentiate the chemopreventive effect of the antiestrogen (AE) tamoxifen against mammary carcinogenesis. The role of n-3FA in breast cancer prevention in humans is controversial. Preclinical and epidemiologic data suggest that n-3FA may be preferentially protective in obese subjects. To directly test the protective effect of n-3FA against breast cancer, we conducted a 2-year, open-label randomized clinical trial in 266 healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast density (BD; ≥25%) detected on their routine screening mammograms. Eligiblewomenwere randomized to one of the following five groups (i) no treatment, control; (ii) raloxifene 60 mg; (iii) raloxifene 30 mg; (iv) n-3FA lovaza 4 g; and (v) lovaza 4 g plus raloxifene 30 mg. The 2-year change in BD, a validated biomarker of breast cancer risk, was the primary endpoint of the study. In subset analysis, we tested the prespecified hypothesis that body mass index (BMI) influences the relationship between plasma n-3FA on BD. While none of the interventions affected BD in the intention-to-treat analysis, increase in plasma DHA was associated with a decrease in absolute breast density but only in participants with BMI >29. Our results suggest that obese women may preferentially experience breast cancer risk reduction from n-3FA administration.
AB - Preclinical data indicate that omega-3 fatty acids (n-3FA) potentiate the chemopreventive effect of the antiestrogen (AE) tamoxifen against mammary carcinogenesis. The role of n-3FA in breast cancer prevention in humans is controversial. Preclinical and epidemiologic data suggest that n-3FA may be preferentially protective in obese subjects. To directly test the protective effect of n-3FA against breast cancer, we conducted a 2-year, open-label randomized clinical trial in 266 healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast density (BD; ≥25%) detected on their routine screening mammograms. Eligiblewomenwere randomized to one of the following five groups (i) no treatment, control; (ii) raloxifene 60 mg; (iii) raloxifene 30 mg; (iv) n-3FA lovaza 4 g; and (v) lovaza 4 g plus raloxifene 30 mg. The 2-year change in BD, a validated biomarker of breast cancer risk, was the primary endpoint of the study. In subset analysis, we tested the prespecified hypothesis that body mass index (BMI) influences the relationship between plasma n-3FA on BD. While none of the interventions affected BD in the intention-to-treat analysis, increase in plasma DHA was associated with a decrease in absolute breast density but only in participants with BMI >29. Our results suggest that obese women may preferentially experience breast cancer risk reduction from n-3FA administration.
UR - http://www.scopus.com/inward/record.url?scp=84964059148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964059148&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-15-0235
DO - 10.1158/1940-6207.CAPR-15-0235
M3 - Article
C2 - 26714774
AN - SCOPUS:84964059148
SN - 1940-6207
VL - 9
SP - 275
EP - 282
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 4
ER -